5468-71-3

Usage

Uses

Used in Agricultural Industry:
3,5-DichloropicolinaMide is used as a herbicidal agent for controlling broadleaf weeds and grasses in various agricultural crops. It is effective due to its mode of action that involves the inhibition of the enzyme protoporhyrinogen oxidase, which disrupts the plant's cellular processes and causes cell death.
Used in Weed Management:
3,5-DichloropicolinaMide is utilized as a key component in weed management strategies to protect crops from unwanted plant species that can compete for resources and reduce yield. Its application helps maintain the health and productivity of agricultural fields by targeting and eliminating specific weeds without causing significant harm to the crops or the environment, when used according to recommended guidelines.

InChI:InChI=1/C6H4Cl2N2O/c7-3-1-4(8)5(6(9)11)10-2-3/h1-2H,(H2,9,11)

Upstream product

• 5439-08-7 methyl 3,5-dichloropyridine-2-carboxylate 

Downstream Products

• 4214-74-8 3,5-dichloropyridin-2-amine 
• 1344675-05-3 C₂₄H₃₁N₅O₄ 
• 1344675-56-4 C₁₈H₂₅ClN₄O₃ 

Relevant academic research and scientific papers

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

Investigation of the pyrazinones as PDE5 inhibitors: Evaluation of regioisomeric projections into the solvent region

We describe the design, synthesis and profiling of a novel series of PDE5 inhibitors. We take advantage of an alternate projection into the solvent region to identify compounds with excellent potency, selectivity and pharmacokinetic profiles.